DVAX

Dynavax Technologies Corporation (DVAX) | Rumor.io

Dynavax Technologies

DVAX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DVAX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jan 12

$DVAX trading above the tender offer price of $15.5, with some speculating about a potential buyer establishing a position prior to making a bid.
There is a disclosure that "Party A" appeared to be still interested in a deal on Dec. 28, after the deal was announced on Dec. 24.
Some analysts believe that GSK should be a motivated buyer of $DVAX due to its more effective hepatitis vaccine, which could have a negative impact on GSK's Twinrix sales.

Generated by AI

Sentiment

Of the messages about DVAX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	69.33% +11.06
Bearish	—	—	—	30.67% -11.06

Bullish· Dec 25

Dynavax Technologies Corporation has agreed to a buyout by Sanofi, offering a 39% cash premium to shareholders.
The share price of DVAX has seen significant gains, increasing from $5 in January 2021 to $15.43.
The stock has experienced a massive attention spike, with an insane volume increase of 30.7M shares, indicating a strong interest in the asset.

Bearish· Dec 24

The $2.2 billion sale price of $DVAX may be too low, considering the company has over $600 million in cash.
Long-time holders of $DVAX may be disappointed with the buyout, which occurred within the trading range of most years, suggesting the company's leadership failed to execute on its potential.
The sale price of $15.50 per share is considered too low by some investors, who believe the company should have been sold for at least $20 per share.

Generated by AI

Topics

Of the messages about DVAX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	0%	0%	3.46%
Macro	0%	0%	0%	16.31%
Earnings	0%	0%	0%	1.73%
Controversies	0%	0%	0%	1.61%
Announcements	100%	100%	100%	60.29%
Analysts	0%	0%	0%	16.6%

Earnings· Nov 4

$DVAX increased revenue guidance for the year to $375-425 million, a significant increase from the previous estimate.
$DVAX reported Q3 earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share and surpassing estimates four times over the last four quarters.
$DVAX's total revenue for the third quarter of 2021 was $108.3 million, beating the Estimize Revenue Consensus by $44.31 million.

Analysts· Jul 31

Analysts at William Blair and RBC Capital have raised their price targets for $DVAX to $30 and $26, respectively, citing the potential for Heplisav approval.
JPMorgan Chase and RBC Capital have upgraded $DVAX to overweight and outperform, respectively, with price targets of $27 and $26.
Analysts at JPMorgan Chase and William Blair have raised their price targets for $DVAX to $27 and $30, respectively, with William Blair also reiterating a buy rating on the stock.

Announcements· Dec 25

Sanofi to acquire Dynavax (DVAX) for $2.2 billion, adding a marketed adult hepatitis B vaccine and a phase 1/2 shingles candidate to its pipeline.
DVAX shares surge 38% after the acquisition announcement, with the company's HEPLISAV-B vaccine and phase 1/2 shingles candidate Z-1018 being secured by Sanofi.
The acquisition provides a 39% cash premium to DVAX shareholders, with Sanofi agreeing to buy the company for $15.50 per share.

Technical Analysis· Nov 5

$DVAX is in the oversold zone on the daily chart, with a gap fill at 15.22 needed to confirm.
The stock needs to stay above 17.30 for a VWAP reversal, which could lead to further gains.
$DVAX's 50DMA is a key level, with the stock's ability to retake and hold it determining its short-term prospects.

Generated by AI

Community

Of the messages about DVAX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	53.22%
Newcomers	100%	100%	100%	46.78%

Regulars· May 2

Dynavax reported a record quarterly net product revenue for its commercialized vaccine in Q1 2023, positioning the company for continued market share gains and clinical pipeline advancements.
The company's GAAP EPS of -$0.19 missed expectations, while revenue of $46.92M beat estimates by $8.33M, indicating a strong start to the year.
Dynavax's commercialized vaccine has achieved free cash flow positivity, with the company expecting to continue its growth trajectory based on its strong pipeline and market position.

Newcomers· Dec 25

Newcomers are excited about the 38.19% price increase in $DVAX, with many noticing the significant volume spike of 30.7M shares.
The acquisition of Dynavax by Sanofi is a major talking point, with many focusing on the addition of a marketed adult hepatitis B vaccine and a phase 1/2 shingles candidate to Sanofi's pipeline.
Some newcomers are identifying $DVAX as a top gainer, using stock screeners to track its performance and considering it for potential investment.

Generated by AI

Also Discussed

Investors talking about DVAX also mention

#	Name	Attention
1	Exelixis Inc.EXEL	0%-0.03
2	Valneva SE Sponsored ADRVALN	0%new
3	Acadia Pharmaceuticals Inc.ACAD	0%+0
4	VBIV - VBI Vaccines Inc.	——
5	MACK - Merrimack Pharmaceuticals, Inc.	——
6	RDUS - Radius Recycling, Inc.	——
7	FOLD - Amicus Therapeutics, Inc.	——
8	GSK plc ADRGSK	0%0
9	EGRX - Eagle Pharmaceuticals, Inc.	——
10	PRTK - Paratek Pharmaceuticals, Inc.	——